Pimagedine: A novel therapy for diabetic nephropathy

Expert Opinion on Investigational Drugs

Volumn 11, Issue 4, 2002, Pages 565-574

  Abdel Rahman, Emaad ^a   Kline Bolton, W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Advanced glycation end products; Diabetes mellitus; Diabetic nephropathy; End stage renal disease; Pimagedine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ASCORBIC ACID; CARNITINE DERIVATIVE; CARNOSINE; COCARBOXYLASE; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOSARTAN; METFORMIN; PENICILLAMINE; PENTOSIDINE; PENTOXIFYLLINE; PERINDOPRIL; PIOGLITAZONE; PLACEBO; PROTEIN KINASE C; PYRIDORIN; PYRIDOXAMINE; PYRIDOXINE DERIVATIVE; PYRUVIC ACID; RAMIPRIL; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; STREPTOZOCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PATHOGENESIS; PROTEIN CROSS LINKING; PROTEIN GLYCOSYLATION; RAT; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036236805     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.4.565     Document Type: Review

References (88)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
3. Intensive insulin therapy in Type II diabetes: Rationale and collaborative clinical trial results
4. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group
5. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
6. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria
7. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes
8. Effect of Irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes
9. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis
10. Incidence and prevalence of ESRD
11. Active site modification of aldose reductase by nitric oxide donors
12. Protein kinase C activation and the development of diabetic complications
13. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat
14. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications
15. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats
16. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
17. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model Type 2 diabetes
18. Nonenzymatic glycosylation of macromolecules. Prospects of pharmacologic modulation
19. Glycation and diabetic complications
20. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions
21. Nutritional and toxicological aspects of the Maillard browning reaction in foods
22. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
23. Amides are novel protein modifications formed by physiological sugars
24. Advanced nonenzymatic glycation endproducts (AGE): Their relevance to aging and the pathogenesis of late diabetic complications
25. N(epsilon)-(carboxymethyl)lysine levels in patients with Type 2 diabetes: Role of renal function
26. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure
27. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
28. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
29. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
30. The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis
31. Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation
32. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine
33. Diamino oxydase (Histaminase)
34. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction
35. Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo
36. Aminoguanidine-provoked leukocyte adherence to rat mesenteric venules: Role of constitutive nitric oxide synthase inhibition
37. Biological effects of aminoguanidine: An update
38. Stabilization of S-adenosylmethionine decarboxylase by aminoguanidine
39. CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: Effects on regulation and stability of the enzyme
40. Advanced glycation end products induce crosslinking of collagen in vitro
41. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats
42. Evaluation of nitic oxide synthesis and the effect of aminoguanidine on diabetic nephropathy
43. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide diabetic rat glomeruli
44. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
45. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions
46. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
47. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C
48. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy
49. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy
50. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from experimental studies
51. Diabetic neuropathy: Pathogenesis and therapy
52. Mechanisms of diabetic vasculopathy: An overview
53. Pharmacological treatment strategies in age-related cataracts
54. Diabetic vascular complications
55. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
56. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats
57. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat
58. Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats
59. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus
60. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats
61. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
62. Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus
63. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding
64. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
65. Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patients with Type I diabetes mellitus
66. Pimagedine (PG) safety profile in patients with Type I diabetes mellitus (DM)
67. Randomized trial of advanced glycosylation end product formation in patients with diabetic nephropathy
68. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II)
69. An AGE-inhibitor aminoguanidine is more effective than enalapril in preventing glomerulosclerosis in experimental diabetes
70. Does combined blockade of the RAS and AGE formation confer superior renoprotection in a hypertensive model of diabetic nephropathy?
71. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation
72. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats
73. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes
74. Renoprotective effects of a novel inhibitor of advanced glycation
75. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation
76. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195
77. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
78. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
79. N-phenacylthiazolium bromide (PTB) decreases renal age levels and increases urinary age excretion, without ameliorating diabetic nephropathy in C57BL/6 mice
80. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
81. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness
82. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys
83. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
84. Inhibitors of advanced glycation end product-associated protein cross-linking
85. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions
86. Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1
87. Suppression of accelerated diabetic altherosclerosis by the soluble receptor for advanced glycation end-products